Resistance data are now requested by the regulatory agencies as an integral part of the approval process of new antiretroviral drugs. We examined the means by which resistance data was gathered during pre-clinical and clinical Phases I, II and III of drug development, and how the public and academic experts access these proprietary data. The analysis identified various opportunities for improvement of the current process, in particular the need for standards in generating and reporting resistance data on new antiretroviral drugs, and the need to enforce warnings in the product labelling on the drug combinations that can potentially lead to resistance and treatment failure.
References
1.
FliegerK.FDA finds new ways to speed treatments to patients. U.S. Food and Drug Administration Consumer Special Report. Washington: U.S. Food and Drug Administration; 1995 [cited 2005, September 21]. Available from: http://www.fda.gov/fdac/special/newdrug/speeding.html.
2.
JohnsonV.A., Brun-VezinetF., ClotetB., ConwayB., D'AquilaR.T., DemeterL.M., KuritzkesD.R., PillayD., SchapiroJ.M., TelentiA., DouglasD., & RichmanD.D.Update of the drug resistance mutations in HIV-1: 2004.Topics in HIV Medicine2004; 12: 119–124.
3.
YeniP.G., HammerS.M., CarpenterC.C., CooperD.A., FischlM.A., GatellJ.M., GazzardB.G., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchechterM., SchooleyR.T., ThompsonM.A., VellaS., & VolberdingP.A.Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.JAMA2004; 292: 251–265.
4.
VandammeA.M., SönnerborgA., Ait-KhaledM., AlbertJ., AsjoB., BachelerL., BanhegyiD., BoucherC., Brun-VézinetF., CamachoR., ClevenberghP., ClumeckN., DedesN., De LucaA., DoerrH.W., FaudonJ.L., GattiG., GerstoftJ., HallW.W., HatzakisA., HellmannN., & HorA.Updated European recommendations for the clinical use of HIV drug resistance testing.Antiviral Therapy2004; 9: 829–848.
5.
Gilead Sciences Inc.Proposed package insert for Viread tablets – version 13 [monograph on the Internet].Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2001[cited 2005, September 21]. Available from: http://www.fda.gov/cder/foi/label/2001/21356lbl.pdf.
6.
U.S. Food and Drug Administration.Approval history, Viread, NDA 21-356 [monograph on the Internet].Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2001 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/foi/appletter/2001/21356ltr.pdf.
7.
FarthingC., KhanlouH., & YehV.Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment of naive HIV-infected patients.Antiviral Therapy2003, 8(Suppl 1), S195.
8.
GlaxoSmithKline.Important drug warning - Early virological non-response in patients with HIV infection treated with lamivudine, abacavir and tenofovir.Pittsburgh: GlaxoSmithKline; 2003 [cited 2005, September 21]. Available from: http://aahivm.org/new/dear_doc_7-25-03.htm.
9.
Gilead Sciences Inc.Important drug warning - High rate of virologic failure in patients with HIV infection treated with a once daily triple NRTI regiment containing didanosine, lamivudine and tenofovir.Foster City: Gilead Sciences Inc; 2003 [cited 2005, September 21]. Available from: http://aahivm.org/new/gilead_letter.pdf.
10.
Gilead Sciences Inc.Viread label, revision NDA 21-356/S-010.Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2004 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/foi/label/2004/21356slr010_viread_lbl.pdf.
11.
HillA.M., & TelentiA.HIV susceptibility testing – time for standards.Antiviral Therapy2004; 9: 463–464.
12.
U.S. Food and Drug Administration.Guidance for industry: Antiviral drug development - conducting virologic studies.Washington: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 2005 [cited 2005, September 21]. Available from: http://www.fda.gov/cder/guidance/6568dft.htm.
13.
OkieS.What ails the FDA?The New England Journal of Medicine2005; 352: 1063–1066.
14.
Food, and Drug Administration. Report on the performance of drug and biological firms in conducting postmarketing commitment studies; availability.Federal Register2004; 69: 12162–12164.
15.
European Federation of Pharmaceutical Industry Associations, International Federation of Pharmaceutical Manufacturers and Associations, Japanese Pharmaceutical Manufacturers Associations, and Pharmaceutical Research and Manufacturers of America.Joint position on the disclosure of clinical trial information via clinical trial registries and databases.Brussles: European Federation of Pharmaceutical Industry Associations; 2005 [cited 2005, September 21]. Available from: http://www.efpia.org/4_pos/sci_regu/Clinicaltrials2005.pdf.
16.
KimE.Y., VrangL., ObergB., & MeriganT.C.Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants.AIDS Research and Human Retroviruses2001; 17: 401–407.
17.
KatlamaC., GhosnJ., TubianaR., WirdenM., ValantinM.A., HarmenbergJ., MardhG., ObergB., & CalvezV.MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.AIDS2004; 18: 1299–1304.
18.
LinP.F., BlairW., WangT., SpicerT., GuoQ., ZhouN., GongY.F., WangH.G., RoseR., YamanakaG., RobinsonB., LiC.B., FridellR., DeminieC., DemersG., YangZ., ZadjuraL., MeanwellN., & ColonnoR.A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.Proceedings of the National Academy of Sciences of the United States of America2003; 100: 11013–11018.
19.
FujiwaraT., SatoA., el-FarrashM., MikiS., AbeK., IsakaY., KodamaM., WuY., ChenL.B., HaradaH., SugimotoH., HatanakaM., & HinumaY.S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.Antimicrobial Agents and Chemotherapy1998; 42: 1340–1345.
20.
LudoviciD.W., De CorteB.L., KuklaM.J., YeH., HoC.Y., LichtensteinM.A., KavashR.W., AndriesK., de BethuneM.P., AzijnH., PauwelsR., LewiP.J., HeeresJ., KoymansL.M., de JongeM.R., Van AkenK.J., DaeyaertF.F., DasK., ArnoldE., & JanssenP.A.Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.Bioorganic and Medicinal Chemistry Letters2001; 11: 2235–2239.
21.
AndriesK., AzijnH., ThielemansT., LudoviciD., KuklaM., HeeresJ., JanssenP., De CorteB., VingerhoetsJ., PauwelsR., & de BethuneM.P.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Antimicrobial Agents and Chemotherapy2004; 48: 4680–4686.
22.
GazzardB.G., PozniakA.L., RosenbaumW., YeniG.P., StaszewskiS., ArastehK., De DierK., PeetersM., WoodfallB., StebbingJ., & vant’ KloosterG.A.An open-label assessment of TMC 125 – a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.AIDS2003; 17: F49–F54.
23.
RicharN., QuanY., SalomonH., HsuM., BedardJ., HarriganP.R., & RandoR., MansourT., BowlinT.L., WainbergM.A.Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC).Antiviral Therapy1999; 4: 171–177.
24.
RichardN., SalomonH., RandoR., MansourT., BowlinT.L., & WainbergM.A.Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa-4′-thio-5-fluorocytidine.Antimicrobial Agents and Chemotherapy2000; 44: 1127–1131.
25.
TaylorD.L., AhmedP.S., TymsA.S., WoodL.J., KellyL.A., ChambersP., ClarkeJ., BedardJ., BowlinT.L., & RandoR.F.Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC].Antimicrobial Agents and Chemotherapy2000; 11: 291–301.
26.
SchinaziR.F., MellorsJ., BazmiH., DiamondS., GarberS., GallagherK., GeleziunasR., KlabeR., PierceM., RaynerM., WuJ.T., ZhangH., HammondJ., BachelerL., ManionD.J., OttoM.J., StuyverL., TrainorG., LiottaD.C., & Erickson-ViitanenS.DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.Antimicrobial Agents and Chemotherapy2002; 46: 1394–1401.
27.
GeleziunasR., GallagherK., ZhangH., BachelerL., GarberS., WuJ.T., ShiG., OttoM.J., SchinaziR.F., & Erickson-ViitanenS.HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor β-d-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset).Antiviral Chemistry and Chemotherapy2003; 14: 49–59.
28.
SchinaziR.F., Schlueter-WirtzS., & StuyverL.Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes.Antiviral Chemistry and Chemotherapy2001; 12 (Suppl 1): 61–65.
29.
KohY., NakataH., MaedaK., OgataH., BilcerG., DevasamudramT., KincaidJ.F., BorossP., WangY.F., TieY., VolarathP., GaddisL., HarrisonR.W., WeberI.T., GhoshA.K., & MitsuyaH.Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.Antimicrobial Agents and Chemotherapy2003; 47: 3123–3129.
30.
YoshimuraK., KatoR., KavlickM.F., NguyenA., MarounV., MaedaK., HussainK.A., GhoshA.K., GulnikS.V., EricksonJ.W., & MitsuyaH.A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.Journal of Virology2002; 76: 1349–1358.
31.
PoppeS.M., SladeD.E., ChongK.T., HinshawR.R., PaganoP.J., MarkowitzM., HoD.D., MoH., GormanR.R.3rd, DuewekeT.J., ThaisrivongsS., & TarpleyW.G.Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.Antimicrobial Agents and Chemotherapy1997; 41: 1058–1063.
32.
BackN.K., van WijkA., RemmerswaalD., van MonfortM., NijhuisM., SchuurmanR., & BoucherC.A.In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.AIDS2000; 14: 101–102.
33.
RusconiS., La Seta CatamancioS., CitterioP., KurtagicS., ViolinM., BalottaC., MoroniM., GalliM., & d'Arminio-MonforteA.Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Antimicrobial Agents and Chemotherapy2000; 44: 1328–1332.
34.
LarderB.A., HertogsK., BloorS., van den EyndeC.H., DeCianW., WangY., FreimuthW.W., & TarpleyG.Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.AIDS2000; 14: 1943–1948.
35.
BulgheroniE., CitterioP., CroceF., Lo CiceroM., ViganoO., SosterF., ChouT.C., GalliM., & RusconiS.Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.The Journal of Antimicrobial Chemotherapy2004; 53: 464–468.
36.
SrinivasR.V., & FridlandA.Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.Antimicrobial Agents and Chemotherapy1998; 42: 1484–1487.
37.
Van RompayK.K., CherringtonJ.M., MarthasM.L., LamyP.D., DaileyP.J., CanfieldD.R., TararaR.P., BischofbergerN., & PedersenN.C.9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.Antimicrobial Agents and Chemotherapy1999; 43: 802–812.
38.
WainbergM.A., MillerM.D., QuanY., SalomonH., MulatoA.S., LamyP.D., MargotN.A., AntonK.E., & CherringtonJ.M.In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.Antiviral Therapy1999; 4: 87–94.
39.
MillerM.D., MargotN.A., HertogsK., LarderB., & MillerV.Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.Nucleosides, Nucleotides and Nucleic Acids2001; 20: 1025–1028.
40.
PalmerS., MargotN., GilbertH., ShawN., BuckheitR.Jr., & MillerM.Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.AIDS Research and Human Retroviruses2001; 17: 1167–1173.
